“Hopeful,” “excited” and “helpful” for the future of women’s health — these are just some of the words expressed by the team that worked together for more than a decade to change the name polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).
PMOS is a chronic condition associated with diabetes, heart disease, depression, infertility, pregnancy complications and a general decreased quality of life. It affects an estimated one in eight women worldwide, and about one in 10 Canadian women, yet the World Health Organization estimates that 70 per cent of those affected have never received a diagnosis.
